AzTrials
AzTrials

HealthyPhase 1NCT05286281

A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803

A Phase 1 study testing PF-07265803 in people with Healthy, run by Pfizer at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to assess the pharmacokinetics, excretion, mass balance and metabolism of PF-07265803 (formerly known as ARRY-371797) in approximately 6 healthy adult male participants. Read more about this study

Who is it for?
Ages 18 years and older, men onlyHealthy volunteers can take part
Conditions the study is for
Healthy
What is being tested?
PF-07265803
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
6 participants
Where
1 siteUnited States
Study dates
31 Mar 2022to 26 May 2022
Phase
Phase 1
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Participants must be male and ≥18 years of age at the time of signing the informed consent.
  • Male participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and electrocardiogram (ECG) monitoring.
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests , lifestyle considerations , and other study procedures.
  • Body Mass Index of 18.0 to 32 kg/m2; and a total body weight >50 kg (110 lb).
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

Who cannot join

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy, gastric bypass, duodenotomy, colectomy, history of inflammatory bowel disease).
  • History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, or HCVAb. Hepatitis B vaccination is allowed.
  • Participants with a history of irregular bowel movements; e.g., less than 1 bowel movement per day, regular episodes of diarrhea or constipation, irritable bowel syndrome (IBS) or lactose intolerance.
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions or situations related to COVID-19 pandemic (eg. Contact with positive case)] that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study intervention with the exception of moderate/potent CYP3A inducers which are prohibited within 14 days plus 5 half-lives prior to the first dose of study intervention.
Show all 22Show fewer
  • Current use of any prohibited concomitant medication(s) or those unwilling/unable to use a permitted concomitant medication(s).
  • Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer).
  • A positive urine drug test.
  • Screening and baseline supine blood pressure (BP) >140 mm Hg (systolic) or >90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is >140 mm Hg (systolic) or >90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
  • Screening and baseline standard 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline QTcF interval >450 msec, atrial fibrillation, complete left bundle branch block (LBBB), signs of an acute or indeterminate age myocardial infarction, ST T interval changes suggestive of myocardial ischemia, second or third degree AV block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is >450 msec, this interval should be rate corrected using the Fridericia method and the resulting QTcF should be used for decision making and reporting. If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTcF or QRS values should be used to determine the participant's eligibility. Computer interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding a participant.
  • Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:
  • Aspartate aminotransferase (AST) or Alanine Aminotransferase (ALT) level ≥ 1.5 × ULN;
  • Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is≤ ULN.
  • History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).
  • Positive urine drug screen or cotinine at screening or check-in, and positive urine alcohol at check-in.
  • Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
  • History of sensitivity to heparin or heparin induced thrombocytopenia.
  • Unwilling or unable to comply with the criteria in the Lifestyle Considerations of this protocol.
  • Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
  • Subjects with exposure to significant diagnostic or therapeutic radiation (eg,serial x ray, computed tomography scan, barium meal) or current employment in a job requiring radiation exposure monitoring within 12 months prior to check-in.
  • Subjects who have participated in more than 3 radiolabeled drug studies in the last 12 months (previous study to be at least 4 months prior to check-in to the study site where exposures are known to the investigator, or 6 months prior to check-in to the study site for a radiolabeled drug study where exposures are not known to the investigator). The total 12-month exposure from this study and a maximum of 2 other previous radiolabeled studies within 4 to 12 months prior to this study will be within the Code of Federal Regulations (CFR) recommended levels considered safe, per United States (US) Title 21 CFR 361.1.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Labcorp Clinical Research Unit

    Madison, Wisconsin, 53704

Other trials in United States

About this study

Official title: A PHASE 1, OPEN-LABEL, SINGLE-PERIOD, NON-RANDOMIZED STUDY TO EVALUATE THE PHARMACOKINETICS, EXCRETION, MASS BALANCE AND METABOLISM OF [14C]PF-07265803 ADMINISTERED ORALLY TO HEALTHY ADULT MALE PARTICIPANTS

The purpose of this study is to assess the pharmacokinetics, excretion, mass balance and metabolism of PF-07265803 (formerly known as ARRY-371797) in approximately 6 healthy adult male participants.

Conditions
Healthy
Being tested
PF-07265803
Keywords
LMNA-related DCM, Cardiomyopathy, Lamin Type A, Heart failure, ARRY-371797
Medical subject headings
Cardiomyopathies, Limb-girdle muscular dystrophy, type 1B, Heart Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PF-07265803Drug

    PF-07265803 is a p38 inhibitor formulated for oral delivery.

Study groups in NCT05286281
Study groupRoleWhat they receive
PF-07265803ExperimentalPF-07265803 is a p38 inhibitor formulated for oral delivery.
Receives: Drug: PF-07265803

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total Recovery of Radioactivity in Urine, Expressed as Percentage of Total Radioactive Dose Administered

    Radioactivity excreted in urine was reported as the percentage of the administered radioactivity excreted at each time interval, cumulatively through that interval and the total percent of dose recovered in urine.

    Measured: Predose, in intervals of 0-6, 6-12, 12-24, 24-48, 48-72, 72-96 hours postdose on Day 1, and each subsequent 24 hours interval up to discharge (maximum 14 days)

  2. Total Recovery of Radioactivity in Feces, Expressed as Percentage of Total Radioactive Dose Administered

    Radioactivity excreted in feces was reported as the percentage of the administered radioactivity excreted at each time interval, cumulatively through that interval and the total percent of dose recovered in feces.

    Measured: Predose, in intervals of each 24 hours post dose on Day 1 up to discharge (maximum 14 days)

  3. Total Recovery of Radioactivity in Total Excretion (Urine + Feces), Expressed as Percentage of Total Radioactive Dose Administered

    Radioactivity excreted in urine and feces was reported as the percentage of the administered radioactivity excreted at each time interval, cumulatively through that interval and the total percent of dose recovered in urine and feces.

    Measured: Predose, in intervals of each 24 hours post dose on Day 1 up to discharge (maximum 14 days)

  4. Relative Abundance of PF-07265803 and Its Metabolites in Plasma, Expressed as Percentage of Radioactivity

    Plasma homogenates were extracted for total radioactivity, and processed samples were analyzed by HPLC with radiochemical detection for quantitation of [14C]PF-07265803-derived components and by HRMS for identification of PF-07265803 and metabolites after a single 400-mg (100 μCi) oral dose of [14C]PF-07265803. Relative abundance of the metabolites of [14C]PF-07265803 in plasma based on [14C] quantitation was reported, expressed as percentage of radioactivity. PF-07265803 and four metabolites identified/characterized in human plasma including PF-07327859, PF-07327890, PF -07327860, and des(dimethylamino)-dioxy-PF-07265803 (m/z 461) were presented below. The plasma analysis was done with a single master pool sample (individual participants pooled based on time and from these a single master pool of all participants in one tube) due to the low amount of radioactivity in the plasma, hence there would be no mean or standard deviation.

    Measured: Predose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72, 96, 120 hours post dose on Day 1

  5. Relative Abundance of PF-07265803 and Its Metabolites in Urine, Expressed as Percentage of Radioactivity

    Urine homogenates were extracted for total radioactivity, and processed samples were analyzed by HPLC with radiochemical detection for quantitation of [14C]PF-07265803-derived components and by HRMS for identification of PF-07265803 and metabolites after a single 400-mg (100 μCi) oral dose of [14C]PF-07265803. In this outcome measure, relative abundance of the metabolites of [14C]PF-07265803 in urine based on [14C] quantitation was reported, expressed as percentage of radioactivity. PF-07265803 and four metabolites identified/characterized in human urine including PF-07327859, PF-07327890, PF-07327891, and des(dimethylamino)-dioxy-PF-07265803 (m/z 461) were presented below.

    Measured: Predose, in intervals of 0-6, 6-12, 12-24, 24-48, 48-72, 72-96 hours postdose on Day 1, and each subsequent 24 hours interval up to discharge (maximum 14 days)

  6. Relative Abundance of PF-07265803 and Its Metabolites in Feces, Expressed as Percentage of Radioactivity

    Fecal homogenates were extracted for total radioactivity, and processed samples were analyzed by HPLC with radiochemical detection for quantitation of [14C]PF-07265803-derived components and by HRMS for identification of PF-07265803 and metabolites after a single 400-mg (100 μCi) oral dose of [14C]PF-07265803. In this outcome measure, relative abundance of the metabolites of [14C]PF-07265803 in feces based on [14C] quantitation was reported, expressed as percentage of radioactivity. PF-07265803 and four metabolites identified/characterized in human urine including PF-07327859, PF-07327890, PF-07327891, and PF-07327860 were presented below.

    Measured: Predose, in intervals of each 24 hours post dose on Day 1 up to discharge (maximum 14 days)

Secondary outcomes (16)

  1. Area Under the Plasma Concentration-Time Profile From Time 0 to Time of the Last Quantifiable Concentration (AUClast) of Total Radioactivity of [14C]PF-07265803 in Plasma

    AUClast is defined as area under the plasma concentration-time profile from time 0 to time of the last quantifiable concentration (Clast). The determination method of AUClast was linear/log trapezoidal rule.

    Measured: Predose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72, 96, 120 hours post dose on Day 1

  2. Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Total Radioactivity of [14C]PF-07265803 in Plasma

    AUCinf is defined as area under the plasma concentration time profile from time zero extrapolated to infinite time.

    Measured: Predose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72, 96, 120 hours post dose on Day 1

  3. Maximum Plasma Concentration (Cmax) of Total Radioactivity of [14C]PF-07265803 in Plasma

    Cmax is defined as maximum plasma concentration. Cmax was observed directly from data.

    Measured: Predose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72, 96, 120 hours post dose on Day 1

  4. Time for Cmax (Tmax) of Total Radioactivity of [14C]PF-07265803 in Plasma

    Tmax is defined as time for Cmax. Tmax was observed directly from data as time of first occurrence.

    Measured: Predose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72, 96, 120 hours post dose on Day 1

  5. Terminal Elimination Half-life (t1/2) of Total Radioactivity of [14C]PF-07265803 in Plasma

    Terminal elimination half-life (t1/2) was the time measured for the plasma concentration to decrease by one half. The determination method of t1/2 was loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Measured: Predose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72, 96, 120 hours post dose on Day 1

  6. AUClast of PF-07265803, PF-07327859, PF-07327860 and PF-07327890 in Plasma

    AUClast is defined as area under the plasma concentration-time profile from time 0 to time of the last quantifiable concentration (Clast). The determination method of AUClast was linear/log trapezoidal rule.

    Measured: Predose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72, 96, 120 hours post dose on Day 1

  7. AUCinf of PF-07265803, PF-07327859, PF-07327860 and PF-07327890 in Plasma

    AUCinf is defined as area under the plasma concentration time profile from time zero extrapolated to infinite time. The determination method of AUCinf was AUClast + (Clast*/ kel), where Clast* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, kel was the terminal phase rate constant.

    Measured: Predose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72, 96, 120 hours post dose on Day 1

  8. Apparent Clearance (CL/F) of PF-07265803 in Plasma

    CL/F is apparent clearance of PF-07265803 from plasma, for extravascular routes of administration. CL/F was calculated with dose/AUCinf.

    Measured: Predose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72, 96, 120 hours post dose on Day 1

  9. Apparent Volume (Vz/F) of PF-07265803 in Plasma

    Vz/F is apparent volume of distribution, estimated from terminal phase, for extravascular dosing. Vz/F was calculated with dose /(AUCinf*kel), where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Measured: Predose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72, 96, 120 hours post dose on Day 1

  10. Cmax of PF-07265803, PF-07327859, PF-07327860 and PF-07327890 in Plasma

    Cmax is defined as maximum plasma concentration. Cmax was observed directly from data.

    Measured: Predose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72, 96, 120 hours post dose on Day 1

  11. Tmax of PF-07265803, PF-07327859, PF-07327860 and PF-07327890 in Plasma

    Tmax is defined as time for maximum plasma concentration (Cmax). Tmax was observed directly from data as time of first occurrence.

    Measured: Predose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72, 96, 120 hours post dose on Day 1

  12. t1/2 of PF-07265803, PF-07327859, PF-07327860 and PF-07327890 in Plasma

    Terminal elimination half-life (t1/2) was the time measured for the plasma concentration to decrease by one half. The determination method of t1/2 was loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Measured: Predose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72, 96, 120 hours post dose on Day 1

  13. Number of Participants With All-Causality and Treatment-Related Treatment-Emergent Adverse Events (TEAEs)

    An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness to study treatment was assessed by the investigator. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study treatment and up to 35 days that were absent before treatment or that worsened relative to pretreatment state.

    Measured: From the first dose of study treatment up to 35 days

  14. Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality

    Laboratory abnormalities included: Hemoglobin (HGB), hematocrit, erythrocytes (ery.) <0.8*lower limit of normal (LLN); ery. mean corpuscular (EMC) volume, EMC HGB, EMC HGB concentration, potassium, chloride, calcium, bicarbonate<0.9*LLN,>1.1*ULN; platelets<0.5*LLN,>1.75*upper limit of normal (ULN); leukocytes, glucose<0.6*LLN,>1.5* ULN; lymphocytes, neutrophils, protein, albumin <0.8*LLN,>1.2*ULN; basophils, eosinophils, monocytes, urate >1.2*ULN; bilirubin (total, direct, indirect)>1.5*ULN; aspartate/alanine aminotransferase, alkaline phosphatase>3.0*ULN; sodium <0.95*LLN,>1.05*ULN; blood urea nitrogen, creatinine >1.3*ULN; Urine: pH<4.5,>8; glucose, ketones, protein, HGB, nitrite, leukocyte esterase>=1. Only those categories in which at least 1 participant had data were reported.

    Measured: From the first dose of study treatment up to 35 days

  15. Number of Participants With Clinically Significant Vital Signs Values

    Vital signs (pulse rate, systolic and diastolic blood pressure) were obtained with participant in the supine position, after having approximately 5 minutes of rest. Clinical significance of vital signs was determined at the investigator's discretion.

    Measured: From the first dose of study treatment up to 35 days

  16. Number of Participants With Clinically Significant Electrocardiogram (ECG) Values

    Standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measures PR, QT, and QTc intervals and QRS complex. Clinical significance of vital signs was determined at the investigator's discretion.

    Measured: From the first dose of study treatment up to 35 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Mar 2022
  2. Study start31 Mar 2022
  3. Primary completion26 May 2022
  4. Study completion26 May 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
6 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05286281
Sponsor's protocol ID
C4411010
Status last verified
Mar 2024
First submitted
14 Feb 2022
Last updated
29 Mar 2024
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing PF-07265803 in people with Healthy, run by Pfizer at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 29 Mar 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total Recovery of Radioactivity in Urine, Expressed as Percentage of Total Radioactive Dose Administered (time frame: Predose, in intervals of 0-6, 6-12, 12-24, 24-48, 48-72, 72-96 hours postdose on Day 1, and each subsequent 24 hours interval up to discharge (maximum 14 days)). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05286281.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2024; AzTrials last refreshed its copy on 6 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in